Jump to content

Durvalumab granted FDA priority review for the treatment of patients with extensive-stage small cell lung cancer.


Recommended Posts

"AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for IMFINZI in combination with standard-of-care (SoC) chemotherapy (etoposide with either cisplatin or carboplatin) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2020...."

Read the whole article here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2019/imfinzi-durvalumab-granted-fda-priority-review-for-the-treatment-of-patients-with-extensive-stage-small-cell-lung-cancer-12022019.html

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.